PGD2R antagonist OC000459 vs placebo
Withdrawals due to adverse events · active EoE patients
1 finding from 1 review
- no estimate extracted1 study · 26 participantsVery low
Findings
What do systematic reviews say?
30 questions · 31 findings · 18 reviews · Gut
No studies found 1 · 3.2%GRADE not reported 2 · 6.5%Very low 12 · 38.7%Low 13 · 41.9%Moderate 3 · 9.7%High 0 · 0%
Vitamin D vs placebo/no treatment
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
- RR 1.97 [0.18, 21.27]12 studies · 1251 participantsVery low
Infliximab 5–10 mg/kg vs placebo
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 2.5 [0.12, 50.54]1 study · 94 participantsVery low
Synbiotic vs placebo
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether synbiotic changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Probiotics for management of functional abdominal pain disorders in children 2023 · Cochrane Headline outcomes onlyRR 4.58 [0.8, 26.19]4 studies · 302 participantsVery low
Probiotics vs placebo
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether probiotic changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Probiotics for management of functional abdominal pain disorders in children 2023 · Cochrane Headline outcomes onlyRR 1 [0.07, 15.12]8 studies · 544 participantsVery low
Probiotics vs placebo
Withdrawals due to adverse events · children with Hirschsprung's disease (HD)
1 finding from 1 review
- Probiotics for the prevention of Hirschsprung‐associated enterocolitis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 60 participantsGRADE not reported
Antibiotics vs placebo
Withdrawals due to adverse events · people with active UC
Antibiotics showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes onlyRR 2.06 [0.27, 15.72]8 studies · 691 participantsLow
Antibiotics plus probiotics vs placebo or no intervention
Withdrawals due to adverse events · people with active UC
It is very uncertain whether antibiotics plus probiotics changes withdrawals due to adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
- Antibiotics for the induction and maintenance of remission in ulcerative colitis 2022 · Cochrane Headline outcomes onlyRR 1 [0.07, 15.08]2 studies · 98 participantsVery low
Synbiotic vs placebo
Withdrawals due to adverse events · children with chronic constipation without a physical explanation
1 finding from 1 review
- no estimate extracted1 study · 155 participantsGRADE not reported
Probiotics vs placebo
Withdrawals due to adverse events · children with chronic constipation without a physical explanation
Probiotic showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 0.64 [0.21, 1.95]5 studies · 357 participantsLow
Antidepressants vs placebo
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Antidepressants for functional abdominal pain disorders in children and adolescents 2021 · Cochrane Headline outcomes onlyRR 3.17 [0.65, 15.33]3 studies · 238 participantsLow
Adalimumab vs placebo
Withdrawals due to adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.59 [0.38, 0.91]4 studies · 1012 participantsModerate
Briakinumab vs placebo
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 0.82 [0.04, 16.34]1 study · 104 participantsLow
Mesalamine vs placebo
Withdrawals due to adverse events · Patients with collagenous colitis
Mesalamine showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 5.92 [0.7, 49.9]1 study · 62 participantsLow
Budesonide vs placebo
Withdrawals due to adverse events · Patients with collagenous colitis
It is very uncertain whether budesonide changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 0.97 [0.43, 2.17]5 studies · 290 participantsVery low
Boswellia serrata vs placebo
Withdrawals due to adverse events · Patients with collagenous colitis
Boswellia serrata extract showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 2.82 [0.12, 64.39]1 study · 31 participantsLow
Anti‐TB therapy vs placebo
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether anti‐TB therapy changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Anti‐tuberculous therapy for maintenance of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.29 [0.6, 2.77]4 studies · 322 participantsVery low
Azathioprine or 6‐mercaptopurine vs placebo
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.7 [0.94, 3.08]8 studies · 510 participantsModerate
5‐ASA vs placebo
Withdrawals due to adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.11 [0.88, 1.38]10 studies · 1833 participantsLow
Azathioprine or 6‐mercaptopurine vs placebo
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes onlyRR 3.12 [1.59, 6.09]7 studies · 661 participantsVery low